Brokerages expect that Ziopharm Oncology Inc (NASDAQ:ZIOP) will report ($0.13) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Ziopharm Oncology’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.14). Ziopharm Oncology reported earnings per share of ($0.15) during the same quarter last year, which indicates a positive year over year growth rate of 13.3%. The business is scheduled to report its next earnings report on Monday, May 7th.
On average, analysts expect that Ziopharm Oncology will report full year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.39). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.74) to ($0.31). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Ziopharm Oncology.
Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.59 million. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis.
Several brokerages recently issued reports on ZIOP. BidaskClub upgraded Ziopharm Oncology from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 4th. Zacks Investment Research downgraded Ziopharm Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. ValuEngine downgraded Ziopharm Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, HC Wainwright set a $10.00 price objective on Ziopharm Oncology and gave the stock a “buy” rating in a research report on Monday, March 5th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. Ziopharm Oncology presently has an average rating of “Hold” and an average target price of $7.50.
Shares of Ziopharm Oncology stock traded up $0.10 during trading on Tuesday, hitting $4.43. 794,078 shares of the company were exchanged, compared to its average volume of 1,633,265. Ziopharm Oncology has a fifty-two week low of $3.33 and a fifty-two week high of $7.88. The company has a market capitalization of $637.95, a P/E ratio of -8.36 and a beta of 1.72.
A number of institutional investors and hedge funds have recently modified their holdings of ZIOP. BlackRock Inc. raised its holdings in Ziopharm Oncology by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock valued at $35,187,000 after acquiring an additional 280,003 shares during the last quarter. Deutsche Bank AG raised its holdings in Ziopharm Oncology by 141.1% in the 4th quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock valued at $1,216,000 after acquiring an additional 172,227 shares during the last quarter. Virtu Financial LLC raised its holdings in Ziopharm Oncology by 877.6% in the 4th quarter. Virtu Financial LLC now owns 98,638 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 88,548 shares during the last quarter. Vident Investment Advisory LLC raised its holdings in Ziopharm Oncology by 38.8% in the 4th quarter. Vident Investment Advisory LLC now owns 293,082 shares of the biotechnology company’s stock valued at $1,213,000 after acquiring an additional 81,940 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new position in Ziopharm Oncology in the 4th quarter valued at $338,000. Institutional investors own 40.15% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Ziopharm Oncology Inc (ZIOP) Will Post Earnings of -$0.13 Per Share” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/zacks-brokerages-anticipate-ziopharm-oncology-inc-ziop-will-post-earnings-of-0-13-per-share.html.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.